NeuroDigest delivers a weekly synthesis of what matters in peer-reviewed neurology — written for clinicians, not algorithms. Every Monday morning, in your inbox.
No spam. Unsubscribe in one click. · Curated by Vincenzo Laterza, MD — Neurologist, Di Venere Hospital, Bari
How it works
Every week we scan JAMA Neurology, Lancet Neurology, Annals of Neurology, Stroke, Brain, and the Multiple Sclerosis Journal.
Every abstract is reviewed and clinically framed — grouping findings by theme, surfacing what changes practice, discarding what does not.
Every edition closes with a single sentence: the most practice-relevant takeaway of the week.
A structured email with every source linked. Read in full, or save for later.
Topics covered every week
High-efficacy therapy trials, NfL thresholds, MRI protocols — the MS evidence that changes practice.
Thrombectomy eligibility, anticoagulation in AF, hypertension targets — the decisions that matter at the bedside.
DBS advances, alpha-synuclein therapeutics, dopaminergic titration — the latest from movement disorder journals.
Cenobamate and beyond, drug-resistant epilepsy surgery data, and updated status epilepticus protocols.
Lecanemab and donanemab trial updates, plasma p-tau, and monitoring frameworks for early AD.
Anti-CGRP monoclonals, gepants, ditans — the evidence for acute and preventive migraine therapy.
Gene therapies, complement inhibitors, and updated diagnostic criteria across the neuromuscular spectrum.
IDH-targeted therapies, immunotherapy in CNS tumours, and updated WHO classification implications.
ASO therapies, CRISPR advances, and diagnostic yield of whole-genome sequencing in neurological disease.
Who reads NeuroDigest
NeuroDigest is written for consultant neurologists, MS specialists, stroke physicians, and neurologists in training who need to stay current without reading hundreds of pages a week.
Sample edition
EARLY HIGH-EFFICACY THERAPY BLUNTS PIRMA
A Latin American cohort showed early high-efficacy DMT exposure significantly reduced the risk of progression independent of relapse and MRI activity versus delayed escalation (Multiple Sclerosis Journal, 2026). These data extend the early-aggressive argument to populations with historically restricted DMT access.
LATE-WINDOW THROMBECTOMY OUTCOMES
Registry data from 14 European centres confirm that penumbra-guided patient selection at 6–24 hours achieves mRS 0–2 at 90 days in 47% of cases, comparable to the early-window historical benchmark (Stroke, 2026).
Join NeuroDigest
Subscribe to receive every Monday edition directly in your inbox.
Unsubscribe anytime · neurodigest.io